Anti-Cancer Technology


Theralase® has a separate division for Photo Dynamic Technology that develops advanced pharmaceutical products and medical devices based on proprietary non-immunosuppressive photodynamic technology, targeting key health care and oncology markets.

The strategy is to build a specialty Biopharma company by developing and commercializing new and innovative products based on its patented photodynamic compounds, lasers, drug and light delivery systems, personalized and a patient specific platform technologies.

The strategy in oncology is to continue the research & development of the anti-cancer portfolio, with transition metal – based Photodynamic Compounds ("PDC") and other new anti-cancer products, and build a commercial platform in Canada and US for clinical use worldwide.

Theralase® Bladder Cancer Clinical Study

Our Anti-Cancer technology has been successfully evaluated in a Phase 1b Clinical Study for Non-Muscle Invasive Bladder Cancer ("NMIBC"). Theralase® has now launched Phase II NMIBC Clinical Study, with five patients treated at the world-renowned Princess Margaret Cancer Centre in Toronto, Canada.

Our TLD-1433 PhotoDynamic Compound (“PDC”) has proven to be highly toxic to bladder cancer cells when activated by light, producing a 100% kill rate at very low concentrations.

In the following video Dr. Girish Kulkarni MD, Surgeon-scientist affiliated with the Department of Surgery, Faculty of Medicine at the University of Toronto discusses the successful completion of this clinical study.



If you are a patient interested in participating in the study, please download the list of all the active sites currently recruiting patients. Please have your healthcare provider contact the principal investigator before you make any decisions. Please note that Theralase cannot provide any additional information on sites currently recruiting patients.

Theralase® is listed on

For patients or practitioners wishing to learn more about the ongoing clinical study, please visit

Partners in Innovation

As part of our continuing mission to design, develop, and manufacture cutting-edge laser technologies for the treatment of pain and the eradication of disease, Theralase has partnered with individuals and groups at the following institutions and organizations:

Research Team

Theralase® has a unique combination of scientific capabilities in medical devises and small light-activated molecules discovery, design and development. This puts us in a strong position to develop the targeted innovative, science based, medical technology platforms required to meet patient needs. To increase the value of our pipeline we are not only applying the best science and technology, but also employing a comprehensive strategy to safeguard our intellectual property through patent protection.

Hong Song

Clinical Research Coordinator

Lothar Lilge

PhD, Scientific Principal Investigator
Professor in the Department of Medical Biophysics at the University of Toronto, Senior Scientist Ontario Cancer Institute, Princess Margaret Cancer Center

Mark Roufaiel

Research Scientist, PhD
Immunolgy - Cardiovascular Biology

Pavel Kaspler

Research Scientist, PhD

Sharath Jakkani

Clinical Research Coordinator

Scientific and Medical Advisory Board

Our Scientific and Medical Advisory Board (SMAB) is comprised of international key opinion leaders and esteemed scientists with broad expertise in biomedical and clinical research, drug discovery and development, as well as, medical device engineering and manufacturing. The SMAB plays an active role in Theralase® pipeline's development with evaluation of in-licensing and partnership opportunities. The SMAB members meet regularly with the Theralase® team to maximize the chances of success of each of TLT and PDT operational divisions platform technology pipelines. Together, members of the Scientific and Medical Advisory Board provide critical evaluation and guidance of our proposed and current programmes to ensure that our research is focused and cutting-edge.

Lothar Lilge

PhD, Scientific Principal Investigator
Professor in the Department of Medical Biophysics at the University of Toronto, Senior Scientist Ontario Cancer Institute, Princess Margaret Cancer Center

Dr. Michael Jewett

Professor of Surgery (Urology) at Univ. of Toronto, Surgical Oncology at Princess Margaret Cancer Centre

Dr. Michael A. O’Donnell

MD, Professor of Urology, University of Iowa
Dr. O’Donnell’s basic and clinical research has a long history of focusing on bladder immunology and bladder cancer immunotherapy

Brian C. Wilson

Dr. Wilson is a Senior Scientist and Head of the Applied Biophotonics group at Princess Margaret Cancer Centre, University Health Network and Professor in the Department of Medical Biophysics at the University of Toronto.

Ashish M. Kamat

Dr Kamat is an internationally recognized expert in urologic oncology and an authority in the management of urologic cancers.